{"id": "article-18065_0", "title": "Azathioprine -- Continuing Education Activity", "content": "Azathioprine (AZA) is a medication used in the management and treatment of active rheumatoid arthritis (RA) and the prevention of kidney transplant rejection. This activity reviews the indications, action, and contraindications for azathioprine as a valuable agent in treating RA and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients with RA and related conditions.", "contents": "Azathioprine -- Continuing Education Activity. Azathioprine (AZA) is a medication used in the management and treatment of active rheumatoid arthritis (RA) and the prevention of kidney transplant rejection. This activity reviews the indications, action, and contraindications for azathioprine as a valuable agent in treating RA and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients with RA and related conditions."}
{"id": "article-18065_1", "title": "Azathioprine -- Continuing Education Activity", "content": "Objectives: Describe the mechanism of action of azathioprine. Identify the most common adverse events associated with azathioprine therapy. Explain the importance of monitoring for patients on azathioprine therapy. Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when monitoring azathioprine to improve patient outcomes. Access free multiple choice questions on this topic.", "contents": "Azathioprine -- Continuing Education Activity. Objectives: Describe the mechanism of action of azathioprine. Identify the most common adverse events associated with azathioprine therapy. Explain the importance of monitoring for patients on azathioprine therapy. Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when monitoring azathioprine to improve patient outcomes. Access free multiple choice questions on this topic."}
{"id": "article-18065_2", "title": "Azathioprine -- Indications", "content": "Azathioprine (AZA)\u00a0is approved by the Food and Drug Administration (FDA)\u00a0for the symptomatic\u00a0treatment of active rheumatoid arthritis. It also has approval as adjunctive therapy for the prevention of kidney transplant rejection. [1] [2]", "contents": "Azathioprine -- Indications. Azathioprine (AZA)\u00a0is approved by the Food and Drug Administration (FDA)\u00a0for the symptomatic\u00a0treatment of active rheumatoid arthritis. It also has approval as adjunctive therapy for the prevention of kidney transplant rejection. [1] [2]"}
{"id": "article-18065_3", "title": "Azathioprine -- Indications", "content": "AZA\u00a0used off-label for the treatment of inflammatory bowel disease, [3] Churg-Strauss syndrome, autoimmune hepatitis (for\u00a0maintenance treatment along with steroids), [4] [5] chronic ITP (second-line agent), [6] lupus nephritis, [1] connective tissue disease-associated ILD, [7] multiple sclerosis, severe myasthenia gravis, recurrent pericarditis, [8] psoriasis, non-infectious uveitis, [9] relapsing polychondritis, [10] dermatomyositis/polymyositis, erythema multiforme, severe and refractory atopic dermatitis, chronic actinic dermatitis, pyoderma gangrenosum, Behcet disease, cutaneous vasculitis, pityriasis rubra pilaris, lichen planus, bullous pemphigoid, and pemphigus vulgaris. [2] [11] Of note, AZA or 6-MP are treatment options for Crohn disease in children as a maintenance treatment. [12]", "contents": "Azathioprine -- Indications. AZA\u00a0used off-label for the treatment of inflammatory bowel disease, [3] Churg-Strauss syndrome, autoimmune hepatitis (for\u00a0maintenance treatment along with steroids), [4] [5] chronic ITP (second-line agent), [6] lupus nephritis, [1] connective tissue disease-associated ILD, [7] multiple sclerosis, severe myasthenia gravis, recurrent pericarditis, [8] psoriasis, non-infectious uveitis, [9] relapsing polychondritis, [10] dermatomyositis/polymyositis, erythema multiforme, severe and refractory atopic dermatitis, chronic actinic dermatitis, pyoderma gangrenosum, Behcet disease, cutaneous vasculitis, pityriasis rubra pilaris, lichen planus, bullous pemphigoid, and pemphigus vulgaris. [2] [11] Of note, AZA or 6-MP are treatment options for Crohn disease in children as a maintenance treatment. [12]"}
{"id": "article-18065_4", "title": "Azathioprine -- Mechanism of Action", "content": "Azathioprine is\u00a0a purine analog that converts to\u00a0its active metabolites,\u00a0mercaptopurine (6-MP) and thioguanine (6-TGN), by the action of hypoxanthine-guanine phosphoribosyltransferase (HPRT) and thiopurine methyltransferase (TPMT)\u00a0enzymes. It then\u00a0inhibits purine synthesis. [13] Its metabolites\u00a0are incorporated into the replicating DNA and halt division.\u00a0AZA metabolites may also mediate most of its immunosuppressive and toxic effects.\u00a0AZA\u00a0is absorbed\u00a0rapidly through the GI system and does not penetrate the blood-brain barrier. It undergoes metabolism in the liver, and excretion is via the kidneys, which\u00a0increases its\u00a0toxicity in renal failure. [2]", "contents": "Azathioprine -- Mechanism of Action. Azathioprine is\u00a0a purine analog that converts to\u00a0its active metabolites,\u00a0mercaptopurine (6-MP) and thioguanine (6-TGN), by the action of hypoxanthine-guanine phosphoribosyltransferase (HPRT) and thiopurine methyltransferase (TPMT)\u00a0enzymes. It then\u00a0inhibits purine synthesis. [13] Its metabolites\u00a0are incorporated into the replicating DNA and halt division.\u00a0AZA metabolites may also mediate most of its immunosuppressive and toxic effects.\u00a0AZA\u00a0is absorbed\u00a0rapidly through the GI system and does not penetrate the blood-brain barrier. It undergoes metabolism in the liver, and excretion is via the kidneys, which\u00a0increases its\u00a0toxicity in renal failure. [2]"}
{"id": "article-18065_5", "title": "Azathioprine -- Administration", "content": "The starting dose\u00a0for AZA\u00a0is\u00a02 to 2.5 mg/kg/day, except for patients with TPMT or NUDT15 gene mutation, in which the starting dose is lower than normal. [14] Dose adjustments are necessary for hepatic and kidney disease. [11]", "contents": "Azathioprine -- Administration. The starting dose\u00a0for AZA\u00a0is\u00a02 to 2.5 mg/kg/day, except for patients with TPMT or NUDT15 gene mutation, in which the starting dose is lower than normal. [14] Dose adjustments are necessary for hepatic and kidney disease. [11]"}
{"id": "article-18065_6", "title": "Azathioprine -- Administration", "content": "AZA tablets may be administered after meals to decrease adverse GI effects. Administration can be by IV push over 5 minutes, at a concentration not exceeding 5 mg/ml. It can be further diluted with NS or DW and administered by intermittent infusion over 30 to 60 minutes. However, it may also be infused over 5 minutes up to over 8 hours.", "contents": "Azathioprine -- Administration. AZA tablets may be administered after meals to decrease adverse GI effects. Administration can be by IV push over 5 minutes, at a concentration not exceeding 5 mg/ml. It can be further diluted with NS or DW and administered by intermittent infusion over 30 to 60 minutes. However, it may also be infused over 5 minutes up to over 8 hours."}
{"id": "article-18065_7", "title": "Azathioprine -- Adverse Effects", "content": "Complications occur in 15 to 28% of patients. [2] Frequent Side Effects [15] [16] [13] [4] [17] [18] [19] [20] [21] [22] [23] [24]", "contents": "Azathioprine -- Adverse Effects. Complications occur in 15 to 28% of patients. [2] Frequent Side Effects [15] [16] [13] [4] [17] [18] [19] [20] [21] [22] [23] [24]"}
{"id": "article-18065_8", "title": "Azathioprine -- Adverse Effects", "content": "Nausea; is the most frequent side effect Dose-dependent. Early-onset nausea usually resolves without dose alteration", "contents": "Azathioprine -- Adverse Effects. Nausea; is the most frequent side effect Dose-dependent. Early-onset nausea usually resolves without dose alteration"}
{"id": "article-18065_9", "title": "Azathioprine -- Adverse Effects", "content": "Fever", "contents": "Azathioprine -- Adverse Effects. Fever"}
{"id": "article-18065_10", "title": "Azathioprine -- Adverse Effects", "content": "Fatigue", "contents": "Azathioprine -- Adverse Effects. Fatigue"}
{"id": "article-18065_11", "title": "Azathioprine -- Adverse Effects", "content": "Arthralgias/myalgia", "contents": "Azathioprine -- Adverse Effects. Arthralgias/myalgia"}
{"id": "article-18065_12", "title": "Azathioprine -- Adverse Effects", "content": "Bone marrow suppression causing pancytopenia, thrombocytopenia, leukopenia - there are reports of dose-dependent, life-threatening cases. This complication correlates with the 6-TGN level There is a higher risk of myelosuppression in patients who take allopurinol or ACEI and in renal insufficiency An increase in the mean corpuscular volume of the red blood cells is also an expected side effect", "contents": "Azathioprine -- Adverse Effects. Bone marrow suppression causing pancytopenia, thrombocytopenia, leukopenia - there are reports of dose-dependent, life-threatening cases. This complication correlates with the 6-TGN level There is a higher risk of myelosuppression in patients who take allopurinol or ACEI and in renal insufficiency An increase in the mean corpuscular volume of the red blood cells is also an expected side effect"}
{"id": "article-18065_13", "title": "Azathioprine -- Adverse Effects", "content": "Rash", "contents": "Azathioprine -- Adverse Effects. Rash"}
{"id": "article-18065_14", "title": "Azathioprine -- Adverse Effects", "content": "Hepatotoxicity: Hepatic injury correlates with a 6-MMP level of more than 5700 pmol/8 x 10^8 RBC.", "contents": "Azathioprine -- Adverse Effects. Hepatotoxicity: Hepatic injury correlates with a 6-MMP level of more than 5700 pmol/8 x 10^8 RBC."}
{"id": "article-18065_15", "title": "Azathioprine -- Adverse Effects", "content": "Hepatotoxicity categorizes into two groups. Acute idiosyncratic liver injury happens in the early course and resolves with stopping the medication. Nodular regenerative hyperplasia occurs in IBD and organ transplant patients several years after therapy.", "contents": "Azathioprine -- Adverse Effects. Hepatotoxicity categorizes into two groups. Acute idiosyncratic liver injury happens in the early course and resolves with stopping the medication. Nodular regenerative hyperplasia occurs in IBD and organ transplant patients several years after therapy."}
{"id": "article-18065_16", "title": "Azathioprine -- Adverse Effects", "content": "Infections (7.4%): Concomitant use of AZA and steroids will increase the risk of PCP in leukopenic patients.", "contents": "Azathioprine -- Adverse Effects. Infections (7.4%): Concomitant use of AZA and steroids will increase the risk of PCP in leukopenic patients."}
{"id": "article-18065_17", "title": "Azathioprine -- Adverse Effects", "content": "Hypersensitivity: symptoms including fever, chills, arthralgia/myalgia, liver abnormalities, erythema nodosum", "contents": "Azathioprine -- Adverse Effects. Hypersensitivity: symptoms including fever, chills, arthralgia/myalgia, liver abnormalities, erythema nodosum"}
{"id": "article-18065_18", "title": "Azathioprine -- Adverse Effects", "content": "Kidney damage", "contents": "Azathioprine -- Adverse Effects. Kidney damage"}
{"id": "article-18065_19", "title": "Azathioprine -- Adverse Effects", "content": "Rare Side Effects [25] [26] [27] [21] [28] [15] [11] [24] Diarrhea Carcinogenesis: cutaneous hyperkeratosis and nonmelanoma skin cancer (SCC)\u00a0in myasthenia gravis (most likely due to increased risk of photosensitivity), solid-organ transplant\u00a0and IBD patients/ lymphoma in transplant and IBD patients Pancreatitis (3.3%): more in females with\u00a0Crohn disease Dose-dependent Usually happens in the first six weeks In the case of pancreatitis, discontinue AZA Alopecia including telogen effluvium, anagen effluvium, and plica neuropathica Macrocytic anemia Sweet syndrome (acute febrile neutrophilic dermatosis) Pneumonitis: in IBD and renal transplant patients Upper airway edema Tremor: in transplant and Crohn patient: dose-dependent", "contents": "Azathioprine -- Adverse Effects. Rare Side Effects [25] [26] [27] [21] [28] [15] [11] [24] Diarrhea Carcinogenesis: cutaneous hyperkeratosis and nonmelanoma skin cancer (SCC)\u00a0in myasthenia gravis (most likely due to increased risk of photosensitivity), solid-organ transplant\u00a0and IBD patients/ lymphoma in transplant and IBD patients Pancreatitis (3.3%): more in females with\u00a0Crohn disease Dose-dependent Usually happens in the first six weeks In the case of pancreatitis, discontinue AZA Alopecia including telogen effluvium, anagen effluvium, and plica neuropathica Macrocytic anemia Sweet syndrome (acute febrile neutrophilic dermatosis) Pneumonitis: in IBD and renal transplant patients Upper airway edema Tremor: in transplant and Crohn patient: dose-dependent"}
{"id": "article-18065_20", "title": "Azathioprine -- Contraindications", "content": "Contraindications [29] [30] [31] [2] [32] Hypersensitivity Pregnancy or plan for pregnancy: Contraception recommended.\u00a0AZA can increase the risk of spontaneous miscarriage, low birth weight, and preterm delivery. Although data in\u00a0systemic lupus erythematosus (SLE)\u00a0and renal transplant patients showed safety in pregnancy. In\u00a0some specific conditions like SLE and antiphospholipid antibody syndrome, the benefits of taking immunosuppressive medications are more than harms\u00a0in keeping the mother safe. Breastfeeding as 6-MP was present in breast-milk of women who take\u00a0azathioprine Unknown TPMT status or deficient TPMT activity due to the high risk of myelosuppression Known malignancy Clinically active infection Relative Contraindications [32] Allopurinol intake concomitantly with AZA due to severe myelosuppression Cyclophosphamide or chlorambucil treatment in the past", "contents": "Azathioprine -- Contraindications. Contraindications [29] [30] [31] [2] [32] Hypersensitivity Pregnancy or plan for pregnancy: Contraception recommended.\u00a0AZA can increase the risk of spontaneous miscarriage, low birth weight, and preterm delivery. Although data in\u00a0systemic lupus erythematosus (SLE)\u00a0and renal transplant patients showed safety in pregnancy. In\u00a0some specific conditions like SLE and antiphospholipid antibody syndrome, the benefits of taking immunosuppressive medications are more than harms\u00a0in keeping the mother safe. Breastfeeding as 6-MP was present in breast-milk of women who take\u00a0azathioprine Unknown TPMT status or deficient TPMT activity due to the high risk of myelosuppression Known malignancy Clinically active infection Relative Contraindications [32] Allopurinol intake concomitantly with AZA due to severe myelosuppression Cyclophosphamide or chlorambucil treatment in the past"}
{"id": "article-18065_21", "title": "Azathioprine -- Monitoring", "content": "It usually requires 6 to 8 weeks\u00a0for\u00a0AZA to\u00a0work. The recommendation is to consider stopping\u00a0the medication\u00a0if there is no improvement\u00a0in 3 months. [2]", "contents": "Azathioprine -- Monitoring. It usually requires 6 to 8 weeks\u00a0for\u00a0AZA to\u00a0work. The recommendation is to consider stopping\u00a0the medication\u00a0if there is no improvement\u00a0in 3 months. [2]"}
{"id": "article-18065_22", "title": "Azathioprine -- Monitoring", "content": "Checking TPMT activity is\u00a0suggested before starting the medication. Misclassification of TMPT phenotype can occur\u00a0by prior blood transfusion. [12]", "contents": "Azathioprine -- Monitoring. Checking TPMT activity is\u00a0suggested before starting the medication. Misclassification of TMPT phenotype can occur\u00a0by prior blood transfusion. [12]"}
{"id": "article-18065_23", "title": "Azathioprine -- Monitoring", "content": "Test the patient for\u00a0hepatitis B and C and PPD. A pregnancy test before treatment initiation is also a recommendation. [32]", "contents": "Azathioprine -- Monitoring. Test the patient for\u00a0hepatitis B and C and PPD. A pregnancy test before treatment initiation is also a recommendation. [32]"}
{"id": "article-18065_24", "title": "Azathioprine -- Monitoring", "content": "Complete blood count (CBC)\u00a0and\u00a0liver function test (LFT)\u00a0monitoring weekly are recommended initially\u00a0for the first\u00a04 to 8 weeks. CBC and LFT should get checked every three months for the rest of the treatment\u00a0once the maintenance dose is achieved. However, it is advisable to check CBC and LFT more frequently in patients with kidney or renal diseases or elderly patients on high dosages of AZA or low TPMT activity. If labs show leukopenia (WBC less than 3 x 10^9/L), thrombocytopenia (platelet less than 120 x 10^9/L), or transaminitis (liver biochemistry more than half of the normal upper limit), the medication should be stopped. [21]", "contents": "Azathioprine -- Monitoring. Complete blood count (CBC)\u00a0and\u00a0liver function test (LFT)\u00a0monitoring weekly are recommended initially\u00a0for the first\u00a04 to 8 weeks. CBC and LFT should get checked every three months for the rest of the treatment\u00a0once the maintenance dose is achieved. However, it is advisable to check CBC and LFT more frequently in patients with kidney or renal diseases or elderly patients on high dosages of AZA or low TPMT activity. If labs show leukopenia (WBC less than 3 x 10^9/L), thrombocytopenia (platelet less than 120 x 10^9/L), or transaminitis (liver biochemistry more than half of the normal upper limit), the medication should be stopped. [21]"}
{"id": "article-18065_25", "title": "Azathioprine -- Monitoring", "content": "If patients have abdominal pain or severe nausea/vomiting, serum amylase requires checking to rule out pancreatitis. Lymph node and skin examination should be biannual. [32] If a generalized wart occurs, the AZA dose should be reduced or switched to another agent.", "contents": "Azathioprine -- Monitoring. If patients have abdominal pain or severe nausea/vomiting, serum amylase requires checking to rule out pancreatitis. Lymph node and skin examination should be biannual. [32] If a generalized wart occurs, the AZA dose should be reduced or switched to another agent."}
{"id": "article-18065_26", "title": "Azathioprine -- Monitoring", "content": "Some\u00a0studies suggested monitoring the level of AZA metabolites (e.g., 6-TGN and 6-MP) to avoid specific complications. [4]", "contents": "Azathioprine -- Monitoring. Some\u00a0studies suggested monitoring the level of AZA metabolites (e.g., 6-TGN and 6-MP) to avoid specific complications. [4]"}
{"id": "article-18065_27", "title": "Azathioprine -- Toxicity", "content": "Toxicity symptoms include\u00a0gastrointestinal symptoms, bradycardia, hepatotoxicity, myelosuppression. [33] Acute toxicity usually happens when more than 1.5 times of daily dose is taken by the patient.", "contents": "Azathioprine -- Toxicity. Toxicity symptoms include\u00a0gastrointestinal symptoms, bradycardia, hepatotoxicity, myelosuppression. [33] Acute toxicity usually happens when more than 1.5 times of daily dose is taken by the patient."}
{"id": "article-18065_28", "title": "Azathioprine -- Toxicity", "content": "In the acute setting, activated charcoal may help with decreasing the symptoms within\u00a0two hours of ingestion. [34] No specific antidote is known for AZA. In severe cases of toxicity, dialysis is permissible as AZA is dialysable. In cases of hepatic sinusoidal obstruction syndrome, it must discontinue permanently. If severely leukopenic, thrombocytopenic, or infected, treatment should stop.", "contents": "Azathioprine -- Toxicity. In the acute setting, activated charcoal may help with decreasing the symptoms within\u00a0two hours of ingestion. [34] No specific antidote is known for AZA. In severe cases of toxicity, dialysis is permissible as AZA is dialysable. In cases of hepatic sinusoidal obstruction syndrome, it must discontinue permanently. If severely leukopenic, thrombocytopenic, or infected, treatment should stop."}
{"id": "article-18065_29", "title": "Azathioprine -- Enhancing Healthcare Team Outcomes", "content": "Azathioprine is an immunomodulator associated with several serious adverse effects.\u00a0Susceptibility to its toxicity\u00a0varies\u00a0with age, genetic differences, and\u00a0medication dosage.\u00a0Its adverse effects are a limiting factor in the patient's compliance. Therefore regular follow-up\u00a0and frequent\u00a0laboratory workups are crucial to avoiding its complications. Clinicians and pharmacists should be aware of potential adverse effects of AZA, even in asymptomatic patients. Pharmacists should verify dosing is appropriate to the condition treated and report any discrepancies to the rest of the healthcare team. Nursing will often function at the \"front lines\" in seeing the patients and are often the first to know about adverse events, which they can report to the team. Nursing will also be in charge of administration, so they should verify dosing to ensure optimal therapeutic results with minimal adverse effects.", "contents": "Azathioprine -- Enhancing Healthcare Team Outcomes. Azathioprine is an immunomodulator associated with several serious adverse effects.\u00a0Susceptibility to its toxicity\u00a0varies\u00a0with age, genetic differences, and\u00a0medication dosage.\u00a0Its adverse effects are a limiting factor in the patient's compliance. Therefore regular follow-up\u00a0and frequent\u00a0laboratory workups are crucial to avoiding its complications. Clinicians and pharmacists should be aware of potential adverse effects of AZA, even in asymptomatic patients. Pharmacists should verify dosing is appropriate to the condition treated and report any discrepancies to the rest of the healthcare team. Nursing will often function at the \"front lines\" in seeing the patients and are often the first to know about adverse events, which they can report to the team. Nursing will also be in charge of administration, so they should verify dosing to ensure optimal therapeutic results with minimal adverse effects."}
{"id": "article-18065_30", "title": "Azathioprine -- Enhancing Healthcare Team Outcomes", "content": "In summary, azathioprine therapy requires an interprofessional team approach, including clinicians, specialists, mid-level practitioners, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]", "contents": "Azathioprine -- Enhancing Healthcare Team Outcomes. In summary, azathioprine therapy requires an interprofessional team approach, including clinicians, specialists, mid-level practitioners, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]"}
{"id": "article-18065_31", "title": "Azathioprine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Azathioprine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}